NASDAQ : APGE
Apogee Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 135.07 USD (Sep 3, 2026, 4:00 PM EDT) · Market cap 10.19B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 10.19B |
| Enterprise Value | 8.90B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.93M |
| Shares Outstanding | 75.42M |
| Shares Change (YoY) | +17.59% |
| Shares Change (QoQ) | +8.29% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 79.10% |
| Float | 58.44M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.49 |
| P/TBV Ratio | 8.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 26.44 |
| Quick Ratio | 26.17 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -204.90 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -32.46% |
| Return on Assets (ROA) | -20.30% |
| Return on Invested Capital (ROIC) | -22.09% |
| Return on Capital Employed (ROCE) | -24.94% |
| Weighted Average Cost of Capital (WACC) | 6.15% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 261 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 280,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +271.38% |
| 50-Day Moving Average | 134.13 |
| 200-Day Moving Average | 91.97 |
| Relative Strength Index (RSI) | 78.68 |
| Average Volume (20 Days) | 1,315,124 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.27M |
| Short Previous Month | 4.22M |
| Short % of Shares Out | 5.67% |
| Short % of Float | 7.31% |
| Short Ratio (days to cover) | 3.63 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -323.75M |
| Pretax Income | -294.09M |
| Net Income | -294.37M |
| EBITDA | -322.12M |
| EBIT | -323.75M |
| Earnings Per Share (EPS) | -$4.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 971.93M |
| Total Debt | 6.83M |
| Net Cash | 1.29B |
| Net Cash Per Share | $17.07 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 15.91 |
| Working Capital | 954.22M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -243.89M |
| Capital Expenditures | -62,000 |
| Depreciation & Amortization | 1.63M |
| Net Borrowing | n/a |
| Free Cash Flow | -243.96M |
| FCF Per Share | -$3.23 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.59% |
| Shareholder Yield | -17.59% |
| Earnings Yield | -2.89% |
| FCF Yield | -2.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $134.85 |
| Price Target Difference | -0.16% |
| Analyst Consensus | Hold |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |